Humacyte Inc
Humacyte Inc (HUMA) Straddle
HUMA straddle scan found 5 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 95.9%.
Read more
Trading a HUMA straddle lets you take a pure volatility position on Humacyte Inc without committing to a direction. Humacyte Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate HUMA straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on HUMA profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Humacyte Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the HUMA straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes.
The company was founded in 2004 and is headquartered in Durham, North Carolina.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the HUMA straddle is the cleanest expression of that view. Our scanner prices every HUMA straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a HUMA straddle into a catalyst or short a HUMA straddle to harvest decay, the options straddle setups that matter are all in one place.
| Jan 21, 2028 | 4.00 | $3.60 | 493 | 75% | 95.9% | $7.60 | $0.40 | 0 |
| Jan 15, 2027 | 1.00 | $0.45 | 122 | 75% | 88.7% | $1.45 | $0.55 | 301 |
| Jan 15, 2027 | 1.50 | $1.05 | 122 | 75% | 81.8% | $2.55 | $0.45 | 1,548 |
| Dec 18, 2026 | 1.00 | $0.65 | 94 | 75% | 75.3% | $1.65 | $0.35 | 422 |
| Jan 21, 2028 | 2.50 | $3.60 | 493 | 75% | — | $6.10 | -$1.10 | 104 |
As of September 16, 2026
Find the right straddle before volatility moves
Track HUMA straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→